Fresenius Provides Flu Vaccine - Analyst Blog
October 12 2011 - 10:00AM
Zacks
Fresenius Medical Care North
America (“FMCNA”), the North American division of Fresenius
Medical Care (FMS), recently revealed that, from October
2011, it will offer its patients as well as clinical employees a
yearly flu vaccine, as a precaution against both H1N1 and seasonal
flu.
Flu is a serious condition for
dialysis patients suffering from kidney failure and can cause
pneumonia among other conditions. Fresenius’ flu vaccination
program reflects its UltraCare mission of providing top-class,
patient-centric care. More information can be found at the company
website.
As per advice from the Centers for
Disease Control and Prevention (“CDC”), patients with chronic
kidney disease (“CKD”) should receive the vaccine annually. CKD is
a degenerative, often permanent, decline in kidney function that
occurs over time. When CKD leads to kidney failure, or End Stage
Renal Disease (“ESRD”), dialysis or kidney transplant is the only
treatment option.
Dialysis is a life-preserving
process that cleanses waste from the blood stream, removes
superfluous fluids and regulates the chemistry of the body when a
person suffers from kidney failure. Patients need regular dialysis
treatment unless they receive a kidney transplant.
Fresenius advises that patients
should contact their nearest Fresenius clinic to find out the
specific flu vaccination timetable. Besides taking the vaccine,
Fresenius provides tips on how to avoid catching the flu, such as,
thoroughly and frequently washing hands with soap and water;
abstaining from touching the mouth, nose and eyes; informing
dialysis providers if one has symptoms of the flu and letting the
clinician know if someone has already received a flu shot from
another source.
Fresenius is the largest provider
of dialysis products and services on the planet. The company
operates a network of about 2,769 dialysis clinics across North
America and overseas markets to provide dialysis treatment to
approximately 216,942 patients worldwide. Fresenius’ principal
competitor in the U.S. is DaVita Inc. (DVA), which
also provides dialysis services to patients suffering from chronic
kidney failure or ESRD.
DAVITA INC (DVA): Free Stock Analysis Report
FRESENIUS MED (FMS): Free Stock Analysis Report
Zacks Investment Research
DaVita (NYSE:DVA)
Historical Stock Chart
From Oct 2024 to Nov 2024
DaVita (NYSE:DVA)
Historical Stock Chart
From Nov 2023 to Nov 2024